Tragara releases Apricoxib results; Metyrapone shows promise for PTSD treatment;

@FierceBiotech: J&J lays out blockbuster R&D strategy, plans for 11 new meds. Story| Follow @FierceBiotech

@JohnCFierce: Amylin, the "jilted lover," gets its temporary restraining order against Lilly. US District Judge Sammartino writes one heck of an order. Filing | Follow @JohnCFierce

> Mountain View, CA-based MAP Pharmaceuticals has submitted its NDA for Levadex, an orally inhaled migraine drug. MAP release

> Tragara Pharmaceuticals presented some positive results for Apricoxib at ASCO. The COX-2 inhibitor reversed epithelial-mesenchymal transition in xenograft models of several types of solid tumors. Tragara release

> A cortisone-blocking drug, metyrapone, offers potential line of attack against post-traumatic stress disorder. Article

> Exton, PA-based Nuron Biotech will use PolyTheric's TheraPEG technology on NU400, a long-acting version of its Phase III multiple sclerosis proprietary recombinant human interferon beta-1b treatment. Nuron release 

> Shares of Belgium's Omega Pharma rise after a report of possible management buyout. Item

> Pharmascience has purchased fellow Canadian biotech Aegera Therapeutics. All Aegera employees will continue to be employed by Pharmascience. Release

Pharma News

@FiercePharma: Amylin wins TRO in fight over Lilly marketing pact. News | Follow @FiercePharma

> Abbott down after NIH halts Niaspan study. Report

> Mylan to launch prescription drugs in India. Piece

> Pharma firms protest UK gov't. pricing decision. Article

> AZ: No more free trips for doctors. Story

> Intercell recalls encephalitis vaccine batch. Article

And Finally... According to a UNC-Chapel Hill study, one in five young adults suffer from hypertension, or high blood pressure. Previous research had shown 4 percent of 20- to 39-year-olds had the condition. News

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.